Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xu-Hao Zhang

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Cost Effectiveness and Resource Allocation : C/E|August 31, 2017
Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in MalaysiaXiao Jun Wang, Ashwini Saha, Xu-Hao Zhang
Human Vaccines & Immunotherapeutics|July 27, 2016
Response to Wu et al. - Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong KongLijoy Varghese, Bruce Mungall, Xu-Hao Zhang, et al.
Patient Preference and Adherence|November 26, 2009
Development and validation of a scale to measure patients' trust in pharmacists in SingaporeXu-Hao Zhang, Jing Jin, Surachat Ngorsuraches, et al.
The Patient|January 26, 2012
Development and validation of a functional health literacy testXu-Hao Zhang, Julian Thumboo, Kok-Yong Fong, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 1, 2010
The impact of health literacy on health-related quality of life (HRQoL) and utility assessment among patients with rheumatic diseasesXu-Hao Zhang, Shu-Chuen Li, Kok-Yong Fong, et al.
Applied Health Economics and Health Policy|April 11, 2018
A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New ZealandLijoy Varghese, Louise Talbot, Andrea Govender, et al.
Value in Health Regional Issues|April 29, 2018
Are English and Chinese Versions of the Audit of Diabetes-Dependent Quality of Life Equivalent? An Exploratory Study Based on the Universalist ApproachXu-Hao Zhang, Kevin Tan, Hwee-Huan Tan, et al.
Value in Health Regional Issues|April 29, 2018
Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for SingaporeGilberto Lopes, Thomas Burke, James Pellissier, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 17, 2008
Applying the Expectancy-Value Model to understand health valuesXu-Hao Zhang, Feng Xie, Hwee-Lin Wee, et al.
Human Vaccines & Immunotherapeutics|November 9, 2017
Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in KoreaXu-Hao Zhang, Oscar Leeuwenkamp, Kyu-Bin Oh, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Cost Effectiveness and Resource Allocation : C/E|August 31, 2017
Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in MalaysiaXiao Jun Wang, Ashwini Saha, Xu-Hao Zhang
Human Vaccines & Immunotherapeutics|July 27, 2016
Response to Wu et al. - Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong KongLijoy Varghese, Bruce Mungall, Xu-Hao Zhang, et al.
Patient Preference and Adherence|November 26, 2009
Development and validation of a scale to measure patients' trust in pharmacists in SingaporeXu-Hao Zhang, Jing Jin, Surachat Ngorsuraches, et al.
The Patient|January 26, 2012
Development and validation of a functional health literacy testXu-Hao Zhang, Julian Thumboo, Kok-Yong Fong, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 1, 2010
The impact of health literacy on health-related quality of life (HRQoL) and utility assessment among patients with rheumatic diseasesXu-Hao Zhang, Shu-Chuen Li, Kok-Yong Fong, et al.
Applied Health Economics and Health Policy|April 11, 2018
A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New ZealandLijoy Varghese, Louise Talbot, Andrea Govender, et al.
Value in Health Regional Issues|April 29, 2018
Are English and Chinese Versions of the Audit of Diabetes-Dependent Quality of Life Equivalent? An Exploratory Study Based on the Universalist ApproachXu-Hao Zhang, Kevin Tan, Hwee-Huan Tan, et al.
Value in Health Regional Issues|April 29, 2018
Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for SingaporeGilberto Lopes, Thomas Burke, James Pellissier, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 17, 2008
Applying the Expectancy-Value Model to understand health valuesXu-Hao Zhang, Feng Xie, Hwee-Lin Wee, et al.
Human Vaccines & Immunotherapeutics|November 9, 2017
Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in KoreaXu-Hao Zhang, Oscar Leeuwenkamp, Kyu-Bin Oh, et al.
Pageof 3